Investors & Media
Marc Kozin is a professional board member, having served on over a dozen boards in a variety of roles and on all committees.
Previously, Mr. Kozin was a career strategy consultant, having served as President of L.E.K. Consulting’s North American practice from 1997 to 2012. He began his career at L.E.K. in 1987 by helping establish the Boston office. He has over 30 years of experience in corporate and business unit strategy consulting, merger and acquisition advisory services, and value management. He also led the development of L.E.K.'s industry leading life science strategic planning practice.
Mr. Kozin has served as a director of UFP Technologies since 2006 where he is lead director. In January 2013, he joined the strategy advisory board of HealthCare Royalty Partners where he is vice chairman. On the non-profit side, he serves on the board of The Greenlight Fund.
Since 2012, Mr. Kozin has served on the boards of Endocyte, a small molecule targeted therapeutic company since sold to Novartis; Dyax, an integrated biotechnology company since sold to Shire; OvaScience, a fertility company since merged with Millendo Therapeutics; and Flex Pharmaceuticals.
Previously, Mr. Kozin served on the boards of directors of Brandwise, Inc., Lynx Therapeutics, Inc., Assurance Medical, Inc., Medical Simulation Corporation, Advizex, and CrunchTime! Information Systems. Mr. Kozin was also on the board of governors at New England Medical Center and the board of DukeEngage for several years. Mr. Kozin received his B.A. with distinction, magna cum laude, in Economics from Duke University. He was also awarded an MBA with distinction from The Wharton School, University of Pennsylvania.